PubMed:32633661 / 263-923 JSONTXT

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":0,"end":660},"obj":"BACKGROUND"}],"text":"Chemotherapy-induced nausea and vomiting (CINV) can be a serious and debilitating adverse effect that is highly feared by cancer patients. For patients receiving moderately emetogenic chemotherapy regimens at our institution in the ambulatory infusion center, palonosetron was selected as the preferred serotonin (5-HT3) antagonist for CINV prophylaxis per the 2016 NCCN Guidelines, when a neurokinin1 antagonist was not included in the prophylactic regimen. The purpose of this study was to evaluate the efficacy of dexamethasone and palonosetron versus granisetron for the prevention of CINV in patients receiving moderately emetogenic chemotherapy regimens."}

{"project":"SMAFIRA_OGER_TEXT","denotations":[{"id":"T14","span":{"begin":21,"end":27},"obj":"D009325"},{"id":"T15","span":{"begin":21,"end":27},"obj":"D009325"},{"id":"T16","span":{"begin":32,"end":40},"obj":"D014839"},{"id":"T17","span":{"begin":32,"end":40},"obj":"D014839"},{"id":"T18","span":{"begin":252,"end":258},"obj":"CVCL_E031"},{"id":"T21","span":{"begin":260,"end":272},"obj":"70561"},{"id":"T19","span":{"begin":260,"end":272},"obj":"D000077924"},{"id":"T20","span":{"begin":260,"end":272},"obj":"CHEBI:85161"},{"id":"T22","span":{"begin":260,"end":272},"obj":"D000077924"},{"id":"T23","span":{"begin":303,"end":312},"obj":"CHEBI:28790"},{"id":"T24","span":{"begin":303,"end":312},"obj":"D012701"},{"id":"T25","span":{"begin":303,"end":312},"obj":"CHEBI:350546"},{"id":"T26","span":{"begin":303,"end":312},"obj":"D012701"},{"id":"T30","span":{"begin":314,"end":319},"obj":"P46098"},{"id":"T31","span":{"begin":314,"end":319},"obj":"O70212"},{"id":"T32","span":{"begin":314,"end":319},"obj":"PR:P35563"},{"id":"T33","span":{"begin":314,"end":319},"obj":"PR:P23979"},{"id":"T34","span":{"begin":314,"end":319},"obj":"PR:000008833"},{"id":"T35","span":{"begin":314,"end":319},"obj":"P23979"},{"id":"T36","span":{"begin":314,"end":319},"obj":"P35563"},{"id":"T37","span":{"begin":314,"end":331},"obj":"D058831"},{"id":"T38","span":{"begin":314,"end":331},"obj":"D058831"},{"id":"T39","span":{"begin":316,"end":319},"obj":"CVCL_1293"},{"id":"T43","span":{"begin":366,"end":370},"obj":"CHEBI:29819"},{"id":"T44","span":{"begin":366,"end":370},"obj":"CHEBI:29308"},{"id":"T45","span":{"begin":402,"end":412},"obj":"CHEBI:48706"},{"id":"T47","span":{"begin":517,"end":530},"obj":"3264"},{"id":"T46","span":{"begin":517,"end":530},"obj":"D003907"},{"id":"T48","span":{"begin":517,"end":530},"obj":"CHEBI:41879"},{"id":"T49","span":{"begin":517,"end":530},"obj":"D003907"},{"id":"T52","span":{"begin":535,"end":547},"obj":"70561"},{"id":"T50","span":{"begin":535,"end":547},"obj":"D000077924"},{"id":"T51","span":{"begin":535,"end":547},"obj":"CHEBI:85161"},{"id":"T53","span":{"begin":535,"end":547},"obj":"D000077924"},{"id":"T54","span":{"begin":555,"end":566},"obj":"26237"},{"id":"T55","span":{"begin":555,"end":566},"obj":"D017829"},{"id":"T56","span":{"begin":555,"end":566},"obj":"D017829"},{"id":"T57","span":{"begin":555,"end":566},"obj":"CHEBI:5537"}],"text":"Chemotherapy-induced nausea and vomiting (CINV) can be a serious and debilitating adverse effect that is highly feared by cancer patients. For patients receiving moderately emetogenic chemotherapy regimens at our institution in the ambulatory infusion center, palonosetron was selected as the preferred serotonin (5-HT3) antagonist for CINV prophylaxis per the 2016 NCCN Guidelines, when a neurokinin1 antagonist was not included in the prophylactic regimen. The purpose of this study was to evaluate the efficacy of dexamethasone and palonosetron versus granisetron for the prevention of CINV in patients receiving moderately emetogenic chemotherapy regimens."}